Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G01 eye drops for visual nerve damage in primary open-angle glaucoma
CTR20260152Phase 2Active
- Sponsor
- Wanming Saibo
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of G01 in open-angle glaucoma (OAG), sponsored by Wanming Saibo. Started Mar 2026; status: active.
02
Drugs
G01
03
Conditions
open-angle glaucoma (OAG)
Beyond the preview
Go deeper on CTR20260152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260152.